Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135485 | 0.84 | FPR3 (0.37) | FPR3FPR2FBP1MAPK10SMN1; SMN2 | |
| SCHEMBL2629266 | 0.78 | SLC6A3 (0.44) | SMN1; SMN2ALDH1A1POLBTLR8TLR7 | |
| SCHEMBL12394759 | 0.77 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1TP53POLBTLR8 | |
| SCHEMBL10271747 | 0.76 | — | — | |
| SCHEMBL19417098 | 0.75 | TRPM5 (0.37) | ALDH1A1 | |
| SCHEMBL1763810 | 0.75 | ALDH1A1 (0.33) | ALDH1A1POLBTLR8TLR7 | |
| SCHEMBL13593857 | 0.75 | ALDH1A1 (0.33) | ALDH1A1POLBTLR8TLR7 | |
| SCHEMBL10121142 | 0.75 | CDK2 (0.40) | SMN1; SMN2ALDH1A1POLBTLR8TLR7 | |
| SCHEMBL12462040 | 0.73 | FDPS (0.39) | FBP1SMN1; SMN2ALDH1A1TP53POLB | |
| SCHEMBL2018856 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300466-B1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2300466-B1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8338604-B2 | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338604-B2 | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338604-B2 | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2300466-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| EP-2144893-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009155389-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155388-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155388-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155389-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | FPR3 1879/4885FPR2 2061/4885FBP1 1601/4885 |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | LIMK1, LIMK2, MAPK1 | FPR3 365/4885FPR2 894/4885FBP1 919/4885 |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP4K2, MAPKAPK2, MAP3K5 | FPR3 4074/4885FPR2 3131/4885FBP1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.